VersaCross RF Transseptal device found to be efficient for TMVR procedures

1548
VersaCross is available in Pigtail and J-tip RF wire configurations

Baylis Medical has announced the publication of data demonstrating procedural efficiency for MitraClip transcatheter mitral valve repair (TMVR) with use of its VersaCross RF Transseptal device, reporting guide delivery from femoral access in under 7.5 minutes.

The VersaCross device features a single radiofrequency (RF)-tipped wire used to introduce the transseptal sheath into the superior vena cava (SVC), gain transseptal access and act as an exchange wire in the left atrium to facilitate MitraClip guide delivery. Typically, this process involves exchanging multiple devices to achieve and maintain transseptal access. The VersaCross platform an exchangeless solution for access-to-delivery of left heart therapy devices.

The publication in Catheterization and Cardiovascular Interventions was led by Anita W Asgar, interventional cardiologist in the Cardiology Division of the Montreal Heart Institute, Montreal, Canada.

Initial findings concluded procedural efficiency, citing 3.3 minutes to gain transseptal access and a subsequent 3.8 minutes to achieve MitraClip Guide delivery, with a 100% success rate. Previously published data cited 16 minutes to gain transseptal access with use of other transseptal solutions. Additionally, researchers noted a reduced number of wire exchanges required, with the ability to reposition puncture location on the fossa ovalis without the need to rewire.

“The VersaCross platform has improved efficiency in my practice. The exchangeless technology allows me to perform precise puncture and delivery of MitraClip guide in under eight minutes, allowing for safer, more efficient and predictable procedures for my patients,” said Asgar.

The VersaCross solution can be customised to meet physician preference and the patient’s needs. This includes J-Tip and Pigtail wire configurations, as well as tailor-built fixed and steerable sheath options.

“Working closely with leading physicians, we identified a clinical need for technology that allows for controlled precision and secure, effortless delivery while minimising procedural steps. We are thrilled to learn that these researchers experienced what we set out to design to meet the needs of both physicians and patients,” said JP Urbanski who led the development of the VersaCross solution at Baylis Medical.


LEAVE A REPLY

Please enter your comment!
Please enter your name here